Seeking Alpha·1d ago
Evommune, Inc. (EVMN) Discusses In Licensing of EVO570 for Autoimmune Diseases Prepared Remarks TranscriptEvommune, Inc. (EVMN) Discusses In Licensing of EVO570 for Autoimmune Diseases Prepared Remarks Transcript
Evotec SE faces a severe operational crisis, with revenue declining -14.8% YoY in Q2 2026 and gross margins turning negative, indicating a fundamental mismatch between its cost structure and shrinking demand.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 5, 2026 | -$0.20-11.9% vs -$0.18 | $185M+18.2% vs $157M |
Q3 2026 Aug 13, 2026 | -$0.17-275.4% vs -$0.05 | $167M-4.5% vs $175M |
Q2 2026 May 6, 2026 | -$0.46-209.5% vs -$0.15 | $214M+4.5% vs $204M |
Q2 2026 Apr 8, 2026 | $0.05-74.0% vs $0.21 | $348M+5.7% vs $329M |
Evommune, Inc. (EVMN) Discusses In Licensing of EVO570 for Autoimmune Diseases Prepared Remarks Transcript
PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced that a pre-recorded webcast will be available at 8:30 a.m. E.T. today. On the webcast, President and Chief Executive Officer Luis Peña and members of the management team will discuss EVO570, a potential best-in-class oral VAV1-directed molecular gl.
Financial performance: Q3 and nine-month Group revenue of €164.9 m and €465.0 m, respectively (Q3: €164.2 m, 9M: €477.4 m at CER); adj. Group EBITDA of -€1.6 m and -€44.3 m, respectively (Q3: -€1.7 m, 9M: -€39.1 m at CER) Robust commercial momentum: Net sales* in D&PD base business increased 24% vs.
PALO ALTO, Calif. & NEW YORK & CHENGDU, China--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing therapies for chronic inflammatory diseases, and Hinova Pharmaceuticals Inc. (SSE: 688302) today announced an exclusive license agreement granting Evommune worldwide rights outside of Greater China to develop, manufacture and commercialize EVO570 (formerly HC118 and known as HP570 in Greater China), an oral VAV1-directed mol.
Benchmark EVO against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Evotec SE (EVO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.69 | $600.36M | -2.93 | -4.98% | -25.47% | -26.04% | — | |
| $271.83 | $44.74B | 32.57 | 5.87% | 8.05% | 21.39% | — | |
| $337.52 | $16.26B | 408.03 | -0.85% | 1.01% | 1.3% | — | |
| $653.11 | $18.23B | 35.78 | 19.97% | 18.24% | 99.76% | — | |
| $105.02 | $14.39B | 337.47 | 2.72% | 5.53% | 4.89% | — | |
| $3.52 | $1.85B | -4.02 | 26.92% | -697.13% | -47.85% | — |
Evotec SE (EVO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when EVO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Evotec SE (EVO) stock FAQ — growth, dividends, profitability & financials explained
Evotec SE (EVO) reported $720.9M in revenue over the trailing twelve months. Revenue was $757.3M in fiscal year 2025. That is 21093% more than the $3.6M of fiscal year 2003.
Evotec SE (EVO) revenue fell by 4.7% over the trailing twelve months, compared with the twelve months before.
No. Evotec SE (EVO) reported a net loss of $183.6M over the trailing twelve months.
Evotec SE (EVO) had a return on equity (ROE) of -26.0% over the trailing twelve months. A negative ROE means the company lost money over the period.
Evotec SE (EVO) had negative free cash flow of $131.3M over the trailing twelve months.
